Gossamer Bio Stock EBITDA

GOSS Stock

USD 1.39 0.06 4.14%

Gossamer Bio fundamentals help investors to digest information that contributes to Gossamer Bio's financial success or failures. It also enables traders to predict the movement of Gossamer Stock. The fundamental analysis module provides a way to measure Gossamer Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gossamer Bio stock.

		Last Reported	Projected for Next Year
	EBITDA	-59.9 M	-62.9 M

EBITDA is likely to drop to about (62.9 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gossamer Bio Company EBITDA Analysis

Gossamer Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Gossamer Bio EBITDA

(59.92 M)

Most of Gossamer Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gossamer Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Gossamer EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Gossamer Bio is extremely important. It helps to project a fair market value of Gossamer Stock properly, considering its historical fundamentals such as EBITDA. Since Gossamer Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gossamer Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gossamer Bio's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Total Liab	Total Current Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Net Receivables	Deferred Long Term Liab	Capital Stock	Common Stock	Property Plant Equipment	Short Term Debt	Short Long Term Debt
Total Assets		-0.55	0.66	-0.19	-0.72	0.83	0.77	0.92	0.77	1.0	0.85	0.89	1.0	-0.07	-0.26	0.57	0.57	0.56	0.44	-0.26
Total Stockholder Equity	-0.55		-0.44	0.24	0.34	-0.35	-0.55	-0.47	-0.43	-0.55	-0.54	-0.55	-0.53	0.13	-0.22	0.02	0.02	-0.27	-0.07	-0.22
Net Tangible Assets	0.66	-0.44		-0.53	-0.16	0.45	0.25	0.35	0.03	0.65	0.44	0.81	0.67	0.41	0.09	0.07	0.07	0.79	-0.12	0.09
Net Debt	-0.19	0.24	-0.53		-0.51	-0.2	0.29	0.12	0.12	-0.18	0.25	-0.12	-0.21	-0.34	-0.48	0.6	0.6	-0.26	0.71	-0.48
Retained Earnings	-0.72	0.34	-0.16	-0.51		-0.65	-0.94	-0.85	-0.77	-0.72	-0.92	-0.69	-0.7	0.49	0.58	-0.92	-0.92	-0.14	-0.9	0.58
Accounts Payable	0.83	-0.35	0.45	-0.2	-0.65		0.77	0.72	0.7	0.83	0.72	0.75	0.83	-0.43	-0.17	0.54	0.54	0.14	0.4	-0.17
Long Term Debt	0.77	-0.55	0.25	0.29	-0.94	0.77		0.83	0.8	0.78	0.95	0.75	0.75	-0.57	-0.35	0.76	0.76	0.07	0.76	-0.35
Long Term Debt Total	0.92	-0.47	0.35	0.12	-0.85	0.72	0.83		0.9	0.92	0.86	0.73	0.91	-0.2	-0.45	0.73	0.73	0.42	0.65	-0.45
Total Liab	0.77	-0.43	0.03	0.12	-0.77	0.7	0.8	0.9		0.77	0.73	0.46	0.75	-0.43	-0.32	0.61	0.61	0.06	0.61	-0.32
Total Current Assets	1.0	-0.55	0.65	-0.18	-0.72	0.83	0.78	0.92	0.77		0.85	0.89	1.0	-0.08	-0.26	0.58	0.58	0.55	0.44	-0.26
Capital Surpluse	0.85	-0.54	0.44	0.25	-0.92	0.72	0.95	0.86	0.73	0.85		0.86	0.82	-0.32	-0.33	0.77	0.77	0.34	0.72	-0.33
Net Invested Capital	0.89	-0.55	0.81	-0.12	-0.69	0.75	0.75	0.73	0.46	0.89	0.86		0.88	-0.06	-0.23	0.56	0.56	0.59	0.43	-0.23
Net Working Capital	1.0	-0.53	0.67	-0.21	-0.7	0.83	0.75	0.91	0.75	1.0	0.82	0.88		-0.07	-0.29	0.57	0.57	0.57	0.43	-0.29
Net Receivables	-0.07	0.13	0.41	-0.34	0.49	-0.43	-0.57	-0.2	-0.43	-0.08	-0.32	-0.06	-0.07		0.31	-0.42	-0.42	0.74	-0.5	0.31
Deferred Long Term Liab	-0.26	-0.22	0.09	-0.48	0.58	-0.17	-0.35	-0.45	-0.32	-0.26	-0.33	-0.23	-0.29	0.31		-0.77	-0.77	-0.03	-0.7	1.0
Capital Stock	0.57	0.02	0.07	0.6	-0.92	0.54	0.76	0.73	0.61	0.58	0.77	0.56	0.57	-0.42	-0.77		1.0	0.12	0.93	-0.77
Common Stock	0.57	0.02	0.07	0.6	-0.92	0.54	0.76	0.73	0.61	0.58	0.77	0.56	0.57	-0.42	-0.77	1.0		0.12	0.93	-0.77
Property Plant Equipment	0.56	-0.27	0.79	-0.26	-0.14	0.14	0.07	0.42	0.06	0.55	0.34	0.59	0.57	0.74	-0.03	0.12	0.12		-0.04	-0.03
Short Term Debt	0.44	-0.07	-0.12	0.71	-0.9	0.4	0.76	0.65	0.61	0.44	0.72	0.43	0.43	-0.5	-0.7	0.93	0.93	-0.04		-0.7
Short Long Term Debt	-0.26	-0.22	0.09	-0.48	0.58	-0.17	-0.35	-0.45	-0.32	-0.26	-0.33	-0.23	-0.29	0.31	1.0	-0.77	-0.77	-0.03	-0.7

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Gossamer Bio

Ebitda Over Time

Gossamer Ebitda

Ebitda

(62.91 Million)

At this time, Gossamer Bio's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Gossamer Bio reported earnings before interest,tax, depreciation and amortization of (59.92 Million). This is 106.83% lower than that of the Biotechnology sector and 159.83% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.54% higher than that of the company.

Gossamer EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gossamer Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gossamer Bio could also be used in its relative valuation, which is a method of valuing Gossamer Bio by comparing valuation metrics of similar companies.

Gossamer Bio is currently under evaluation in ebitda category among its peers.

Gossamer Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Gossamer Bio from analyzing Gossamer Bio's financial statements. These drivers represent accounts that assess Gossamer Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gossamer Bio's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	662.5M	846.5M	183.5M	139.3M	204.6M	194.4M
Enterprise Value	360.2M	848.3M	297.3M	319.6M	361.5M	589.3M

Gossamer Bio Institutional Holders

Institutional Holdings refers to the ownership stake in Gossamer Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gossamer Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gossamer Bio's value.

		Shares
Siren, L.l.c.	2024-12-31	5.2 M
Eversept Partners, Llc	2024-12-31	5 M
Hillhouse Capital Advisors, Ltd.		5 M
Opaleye Management Inc	2024-12-31	4.5 M
Millennium Management Llc	2024-12-31	3.6 M
Ci Private Wealth Llc	2024-12-31	3.4 M
Rock Springs Capital Management Lp	2024-12-31	3.3 M
Junked Platinum Investment Management Ltd	2024-12-31	3.2 M
Blackrock Inc	2024-12-31	3 M
Octagon Capital Advisors Lp	2024-12-31	18.4 M
Nea Management Company, Llc	2024-12-31	18.1 M

Gossamer Fundamentals

	Return On Equity	-1.23
	Return On Asset	-0.12
	Profit Margin	(0.49) %
	Operating Margin	(3.85) %
	Current Valuation	236.94 M
	Shares Outstanding	226.6 M
	Shares Owned By Insiders	3.28 %
	Shares Owned By Institutions	76.49 %
	Number Of Shares Shorted	5.72 M
	Price To Earning	(4.61) X
	Price To Book	11.14 X
	Price To Sales	2.86 X
	Revenue	114.7 M
	Gross Profit	114.7 M
	EBITDA	(59.92 M)
	Net Income	(56.53 M)
	Cash And Equivalents	304.38 M
	Cash Per Share	3.29 X
	Total Debt	201.92 M
	Debt To Equity	3.86 %
	Current Ratio	5.93 X
	Book Value Per Share	0.13 X
	Cash Flow From Operations	(3.47 M)
	Short Ratio	3.23 X
	Earnings Per Share	(0.25) X
	Price To Earnings To Growth	(0.63) X
	Target Price	7.61
	Number Of Employees	135
	Beta	1.86
	Market Capitalization	328.58 M
	Total Asset	315.29 M
	Retained Earnings	(1.27 B)
	Working Capital	264.88 M
	Current Asset	441.63 M
	Current Liabilities	39.84 M
	Net Asset	315.29 M

About Gossamer Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gossamer Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gossamer Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gossamer Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Gossamer Stock Analysis

When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC